Novo Nordisk, the world leader in insulin products, took a big hit this year when the FDA denied approval of its newest long-lasting insulin drug, Tresiba. But CEO Lars Rebien Sørensen is taking every opportunity to let the markets know that Novo has lots of growth in its business.
Sanofi has peeled back the cover on another chapter of Phase III data for U300, advancing its case that its next-gen diabetes therapy can be safer and just as effective as its blockbuster Lantus as it sets the stage for a regulatory pitch next year. But analysts may be left wondering if the long-acting insulin can successfully beat back rivals with a better set of data.
AstraZeneca and Bristol-Myers grabbed a win in the EU today for one of the drugs sprung from their diabetes treatment partnership. But the recommended approval comes even as questions have bubbled up about the future of that relationship.
While other areas of its business have stumbled, Eli Lilly has been betting on diabetes treatments to help it pull through a bad patch. And like a gambler on a winning streak, Eli Lilly will double down on its investments in insulin production with expansions at plants in China, France, Puerto Rico and the U.S. This is after having doubled its bet earlier this year.
When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there helped make up for hundreds of millions lost to generic competition. But now, Bristol-Myers says it's getting out of the diabetes discovery business. Will the company back away from its diabetes partnership next?
Bayer has taken another step toward fulfilling blockbuster ambitions for its eye drug Eylea. The German drugmaker asked European regulators to approve the vision-loss treatment for patients with diabetic macular edema. With diabetes on the rise all over the world, the new indication could offer long-term growth for the already fast-rising drug.
The Swiss drugmaker is wading into research that could top the GLP-1 diabetes-fighting class by adding one of the drugs to another imitation hormone, GIP, for a combination treatment.
GLP-1 drugs have long been one of the hottest targets in diabetes R&D, attracting the attention of the all of the giants that play in this blockbuster market. But now Roche has its eye on an early-stage program that could do GLP-1 drugs one better.
Last quarter, Eli Lilly managed to up its earnings through raising prices and slashing its workforce. This quarter, the Indianapolis pharma giant built on that strategy while adding some higher revenues from diabetes products into the mix. But at least some analysts are skeptical whether Lilly can hang its hat on its diabetes franchise going forward.
Some analysts wanted to know what Lilly's Plan B is, given the fresh wave of generic competition that's about to hit its biggest franchise. What happens if Lilly's current crop of late-stage drugs--frequently touted at the top as one of the biggest and best in the industry--fails to deliver soon?